Business
Data demonstrates key advantages of Parsortix
Data demonstrates key advantages of Parsortix.
About this update from Cellbxhealth Plc
[{"type":"text","content":"\n \nRNS Number : 1262D Angle PLC 17 February 2020 \n\n \n\n\n\nFor immediate release\n\n\n17 February 2020\n\n\n\n \nANGLE plc (\"the Company\")\n \nLEADING KOL PUBLISHES ANALYTICAL AND CLINICAL DATA DEMONSTRATING KEY ADVANTAGES OF PARSORTIX SYSTEM \n \nHamburg-Eppendorf developed validated standardised Parsortix protocols for use in future clinical trials \n \nParsortix harvested cells allow for \"robust amplification of single cell DNA at excellent quality for subsequent molecular analysis\"\n \n \nANGLE plc (AIM:AGL OTCQX:ANPCY), a world-leading liquid biopsy company, is pleased to announce that University Medical Centre Hamburg-Eppendorf has published results of work undertaken to assess the analytical and clinical performance of Parsortix in multiple metastatic cancer types with the main emphasis on metastatic breast cancer. \n \nThe work was completed as part of the pan-European CANCER-ID consortium funded by the European Innovative Medicine Initiative (IMI), which aims to standardise protocols and validate innovative circulating tumour cell (CTC) detection approaches for future clinical trials. \n \nThe results demonstrated the capability of the Parsortix system to work with multiple different cancer types, using multiple blood preservative tube types, and importantly capturing the full range of CTCs, not just epithelial CTCs.\n \nThe researchers demonstrated that the CTCs harvested by the Parsortix system were suitable for \"robust amplification of single cell DNA at excellent quality for subsequent molecular analysis\". Even in metastatic NSCLC (non small cell lung cancer) and gastrointestinal cancer, which are known to be problematic for CTC enrichment, the Parsortix workflow harvested CTCs in 46% of patients notwithstanding treatment and disease condition. The researchers stated in the publication that they had established optimised enrichment protocols, utilising Parsortix, which ensured robust performance.\n \nThe research has been published as a peer-reviewed publication in the journal Cancers and may be accessed via https://angleplc.com/library/publications/. \n \n \nANGLE Founder and Chief Executive, Andrew Newland, commented:\n\"This publication adds to the body of evidence supporting the use o...